{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:01:40Z","timestamp":1790928100734,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T00:00:00Z","timestamp":1510617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf - Case Rep"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40800-017-0055-y","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T09:51:48Z","timestamp":1510653108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Ichthyosiform Pityriasis Rubra Pilaris-Like Eruption Secondary to Ponatinib Therapy: Case Report and Literature Review"],"prefix":"10.1007","volume":"4","author":[{"given":"Ariel E.","family":"Eber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyx","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate E.","family":"Oberlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Giubellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,14]]},"reference":[{"key":"55_CR1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031\u20137.","journal-title":"N Engl J Med."},{"key":"55_CR2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1529-8019.2011.01431.x","volume":"24","author":"I Amitay-Laish","year":"2011","unstructured":"Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther. 2011;24:386\u201395.","journal-title":"Dermatol Ther."},{"key":"55_CR3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1684\/ejd.2015.2684","volume":"26","author":"E Dervis","year":"2016","unstructured":"Dervis E, Ayer M, Akin Belli A, Barut SG. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: a six-year follow up. Eur J Dermatol. 2016;26:133\u20137.","journal-title":"Eur J Dermatol."},{"key":"55_CR4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/ejh.12052","volume":"90","author":"AM Drucker","year":"2013","unstructured":"Drucker AM, Wu S, Busam KJ, Berman E, Amitay-Laish I, Lacouture ME. Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. Eur J Haematol. 2013;90:142\u201350.","journal-title":"Eur J Haematol."},{"key":"55_CR5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.26249","volume":"118","author":"FE Nicolini","year":"2012","unstructured":"Nicolini FE, Turkina A, Shen ZX, et al. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Cancer. 2012;118:118\u201326.","journal-title":"Cancer."},{"key":"55_CR6","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1535-7163.MCT-10-1044","volume":"10","author":"JM Gozgit","year":"2011","unstructured":"Gozgit JM, Wong MJ, Wardwell S, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011;10:1028\u201335.","journal-title":"Mol Cancer Ther."},{"key":"55_CR7","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367:2075\u201388.","journal-title":"N Engl J Med"},{"key":"55_CR8","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783\u201396.","journal-title":"N Engl J Med"},{"key":"55_CR9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000437383","volume":"232","author":"AB Patel","year":"2016","unstructured":"Patel AB, Solomon AR, Mauro MJ, Ehst BD. Unique cutaneous reaction to second- and third-generation tyrosine kinase inhibitors for chronic myeloid leukemia. Dermatology. 2016;232:122\u20135.","journal-title":"Dermatology."},{"key":"55_CR10","first-page":"59","volume":"25","author":"OM Orenay","year":"2016","unstructured":"Orenay OM, Tamer F, Sarifakioglu E, Yildirim U. Lamellar ichthyosis-like eruption associated with ponatinib. Acta Dermatovenerol Alp Pannonica Adriat. 2016;25:59\u201360.","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat."},{"key":"55_CR11","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/bjd.13692","volume":"173","author":"A Alloo","year":"2015","unstructured":"Alloo A, Sheu J, Butrynski JE, et al. Ponatinib-induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities. Br J Dermatol. 2015;173:574\u20137.","journal-title":"Br J Dermatol."},{"key":"55_CR12","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/j.jaad.2013.04.061","volume":"69","author":"A Jack","year":"2013","unstructured":"Jack A, Mauro MJ, Ehst BD. Pityriasis rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib. J Am Acad Dermatol. 2013;69:e249\u201350.","journal-title":"J Am Acad Dermatol."},{"key":"55_CR13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000448750","volume":"62","author":"D Renzi","year":"2017","unstructured":"Renzi D, Marchesi F, De Angelis G, et al. Ponatinib induces a persistent molecular response and graft-versus-host disease\/graft-versus-leukemia effect in a patient with philadelphia-positive acute lymphoblastic leukemia with a T315I mutation following early relapse after allogeneic transplant. Chemotherapy. 2017;62:58\u201361.","journal-title":"Chemotherapy."},{"key":"55_CR14","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3892\/ol.2013.1706","volume":"7","author":"M Inokuchi","year":"2014","unstructured":"Inokuchi M, Ishikawa S, Furukawa H, et al. Treatment of capecitabine-induced hand-foot syndrome using a topical retinoid: a case report. Oncol Lett. 2014;7:444\u20138.","journal-title":"Oncol Lett."},{"key":"55_CR15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1083\/jcb.105.1.427","volume":"105","author":"R Kopan","year":"1987","unstructured":"Kopan R, Traska G, Fuchs E. Retinoids as important regulators of terminal differentiation: examining keratin expression in individual epidermal cells at various stages of keratinization. J Cell Biol. 1987;105:427\u201340.","journal-title":"J Cell Biol."}],"container-title":["Drug Safety - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40800-017-0055-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40800-017-0055-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40800-017-0055-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T20:15:30Z","timestamp":1603311330000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40800-017-0055-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,14]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["55"],"URL":"https:\/\/doi.org\/10.1007\/s40800-017-0055-y","relation":{},"ISSN":["2199-1162","2198-977X"],"issn-type":[{"value":"2199-1162","type":"print"},{"value":"2198-977X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,14]]},"article-number":"19"}}